Reply [5]

Annals of Neurology

Volumn 63, Issue 1, 2008, Pages 126-127

  Trojano, Maria ^a   Pellegrini, Fabio ^b   Fuiani, Aurora ^a   Paolicelli, Damiano ^a   Zipoli, Valentina ^c   Zimatore, Giovanni B ^a   Di Monte, Elisabetta ^a   Portaccio, Emilio ^c   Lepore, Vito ^a   Livrea, Paolo ^a   Amato, Maria Pia ^c  

^a UNIVERSITY OF BARI   (Italy)

^b Consorzio Mario Negri Sud ^*  (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

DISEASE COURSE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; HUMAN; LETTER; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 39049085358     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21230     Document Type: Letter

References (5)

1. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306.
2. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
3. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized studies. Stat Med 2007;26:20-36.
4. Normand SLT, Sykora K, Li P, et al. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005;330:1021-1023.
5. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998;54:948-963.